Mireille Canal-Raffin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mireille Canal-Raffin has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Mathieu Molimard
Department of Medical Pharmacology Bordeaux University Bordeaux France
16 shared publications Béatrice Martinez
INSERM U1219, Université de Bordeaux, 33076 Bordeaux, France; Univ. of Bordeaux, 33076 Bordeaux, France
9 shared publicationsKarine Titier
Laboratoire de Pharmacologie Clinique et Toxicologie, 33076 Bordeaux, France
8 shared publicationsCatherine Verdun-Esquer
Service Santé Travail Environnement, CHU de Bordeaux, Bordeaux 33076, France
7 shared publicationsAntoine Villa
Centre Régional de Pathologies Professionnelles et Environnementales, AP-HM, Marseille 13005, France; Equipe CEReSS, Aix-Marseille-Université, Marseille 13005, France
6 shared publications- Catherine Verdun-Esquer
CHU de Bordeaux, Bordeaux, France
6 shared publications
Latest Publications
- Open Access
- 23 June 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 495, 138933
Experimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studies
- 23 June 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 495, 138933
Open AccessExperimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studies
- 28 September 2023
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 254, 114264
Factors associated with internal contamination of nurses by antineoplastic drugs based on biomonitoring data from a previous study
- 28 September 2023
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 254, 114264
Factors associated with internal contamination of nurses by antineoplastic drugs based on biomonitoring data from a previous study
- 6 August 2022
- Published by Elsevier in Journal of Chromatography B
- Vol. 1209, 123411
Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive UHPLC-MS/MS method in MRM3 mode
- 6 August 2022
- Published by Elsevier in Journal of Chromatography B
- Vol. 1209, 123411
Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive UHPLC-MS/MS method in MRM3 mode
- 22 May 2021
- Published by Springer Nature in International Archives of Occupational and Environmental Health
- Vol. 94 (8) , 1839-1850
Nurses’ internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study
Objective The aim of this study was to assess internal antineoplastic drugs (ADs) contamination in the nursing staff in French hospital centers, using highly sensitive analytical methods. Methods This cross-sectional study included nurses practicing in care departments where at least one of the five ADs studied was handled (5-fluorouracil, cyclophosphamide, doxorubicin, ifosfamide, methotrexate). The nurses study participation lasted 24 h including collection of three urine samples and one self-questionnaire. All urine samples were assayed by ultra-high-performance liquid chromatography–tandem mass spectrometry methods with very low value of the lower limit of quantification (LLOQ). Results 74 nurses were included, 222 urine samples and 74 self-questionnaires were collected; 1092 urine assays were performed. The percentage of nurses with internal AD contamination was 60.8% and low levels of urinary concentrations were measured. Regarding nurses with internal contamination (n = 45), 42.2% presented internal contamination by methotrexate, 37.8% by cyclophosphamide, 33.3% by ifosfamide, 17.8% by 5-fluorouracil metabolite and 6.7% by doxorubicine. Among the positive assays, 17.9% (n = 26/145) were not explained by exposure data from the self-questionnaire but this could be due to the skin contact of nurses with contaminated work surfaces. Conclusions This study reported high percentage of nurses with internal ADs contamination. The low LLOQ values of the used analytical methods, allowed the detection of ADs that would not have been detected with the current published methods: the percentage of contamination would have been 17.6% instead of the 60.8% reported here. Pending toxicological reference values, urine ADs concentrations should be reduced as low as reasonably achievable (ALARA principle).
- 22 May 2021
- Published by Springer Nature in International Archives of Occupational and Environmental Health
- Vol. 94 (8) , 1839-1850
Nurses’ internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study
Objective The aim of this study was to assess internal antineoplastic drugs (ADs) contamination in the nursing staff in French hospital centers, using highly sensitive analytical methods. Methods This cross-sectional study included nurses practicing in care departments where at least one of the five ADs studied was handled (5-fluorouracil, cyclophosphamide, doxorubicin, ifosfamide, methotrexate). The nurses study participation lasted 24 h including collection of three urine samples and one self-questionnaire. All urine samples were assayed by ultra-high-performance liquid chromatography–tandem mass spectrometry methods with very low value of the lower limit of quantification (LLOQ). Results 74 nurses were included, 222 urine samples and 74 self-questionnaires were collected; 1092 urine assays were performed. The percentage of nurses with internal AD contamination was 60.8% and low levels of urinary concentrations were measured. Regarding nurses with internal contamination (n = 45), 42.2% presented internal contamination by methotrexate, 37.8% by cyclophosphamide, 33.3% by ifosfamide, 17.8% by 5-fluorouracil metabolite and 6.7% by doxorubicine. Among the positive assays, 17.9% (n = 26/145) were not explained by exposure data from the self-questionnaire but this could be due to the skin contact of nurses with contaminated work surfaces. Conclusions This study reported high percentage of nurses with internal ADs contamination. The low LLOQ values of the used analytical methods, allowed the detection of ADs that would not have been detected with the current published methods: the percentage of contamination would have been 17.6% instead of the 60.8% reported here. Pending toxicological reference values, urine ADs concentrations should be reduced as low as reasonably achievable (ALARA principle).
- 1 November 2020
- Published by Elsevier in Journal of Chromatography B
- Vol. 1156, 122305
A highly sensitive UHPLC-MS/MS method for urine biological monitoring of occupational exposure to anthracycline antineoplastic drugs and routine application
- 1 November 2020
- Published by Elsevier in Journal of Chromatography B
- Vol. 1156, 122305
A highly sensitive UHPLC-MS/MS method for urine biological monitoring of occupational exposure to anthracycline antineoplastic drugs and routine application
- Open Access
Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study
Introduction Antineoplastic drugs (AD) are potentially carcinogenic and/or reprotoxic molecules. Healthcare professionals are increasingly exposed to these drugs and can be potentially contaminated by them. Internal contamination of professionals is a key concern for occupational physicians in the assessment and management of occupational risks in healthcare settings. Objectives of this study are to report AD internal contamination rate in nursing staff and to identify factors associated with internal contamination. Methods and analysis This trial will be conducted in two French hospital centres: University Hospital of Bordeaux and IUCT-Oncopole of Toulouse. The target population is nurses practicing in one of the fifteen selected care departments where at least one of the five studied AD is handled (5-fluorouracil, cyclophosphamide, doxorubicin, ifosfamide, methotrexate). The trial will be conducted with the following steps: (1) development of analytical methods to quantify AD urine biomarkers, (2) study of the workplace and organization around AD in each care department (transport and handling, professional practices, personal and collective protection equipments available) (3) development of a self-questionnaire detailing professional activities during the day of inclusion, (4) nurses inclusion (urine samples and self-questionnaire collection), (5) urine assays, (6) data analysis. Ethics and dissemination The study protocol has been approved by the French Advisory Committee on the Treatment of Information in Health Research (CCTIRS) and by the French Data Protection Authority (CNIL). Following the opinion of the Regional Committee for the Protection of Persons, this study is outside the scope of the provisions governing biomedical research and routine care (n°2014/87). The results will be submitted to peer-reviewed journals and reported at suitable national and international meetings. Trial registration number NCT03137641.
Open AccessStudy protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study
Introduction Antineoplastic drugs (AD) are potentially carcinogenic and/or reprotoxic molecules. Healthcare professionals are increasingly exposed to these drugs and can be potentially contaminated by them. Internal contamination of professionals is a key concern for occupational physicians in the assessment and management of occupational risks in healthcare settings. Objectives of this study are to report AD internal contamination rate in nursing staff and to identify factors associated with internal contamination. Methods and analysis This trial will be conducted in two French hospital centres: University Hospital of Bordeaux and IUCT-Oncopole of Toulouse. The target population is nurses practicing in one of the fifteen selected care departments where at least one of the five studied AD is handled (5-fluorouracil, cyclophosphamide, doxorubicin, ifosfamide, methotrexate). The trial will be conducted with the following steps: (1) development of analytical methods to quantify AD urine biomarkers, (2) study of the workplace and organization around AD in each care department (transport and handling, professional practices, personal and collective protection equipments available) (3) development of a self-questionnaire detailing professional activities during the day of inclusion, (4) nurses inclusion (urine samples and self-questionnaire collection), (5) urine assays, (6) data analysis. Ethics and dissemination The study protocol has been approved by the French Advisory Committee on the Treatment of Information in Health Research (CCTIRS) and by the French Data Protection Authority (CNIL). Following the opinion of the Regional Committee for the Protection of Persons, this study is outside the scope of the provisions governing biomedical research and routine care (n°2014/87). The results will be submitted to peer-reviewed journals and reported at suitable national and international meetings. Trial registration number NCT03137641.
- 20 August 2018
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 30 (3) , 169-170
La surveillance biologique de l’exposition professionnelle (SBEP) aux médicaments anticancéreux : propositions pour sa mise en œuvre
- 20 August 2018
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 30 (3) , 169-170
La surveillance biologique de l’exposition professionnelle (SBEP) aux médicaments anticancéreux : propositions pour sa mise en œuvre
- 20 August 2018
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 30 (3) , 186-187
La surveillance biologique de l’exposition professionnelle au 5-fluoro-uracile par une méthode analytique de haute sensibilité
- 20 August 2018
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 30 (3) , 186-187
La surveillance biologique de l’exposition professionnelle au 5-fluoro-uracile par une méthode analytique de haute sensibilité
- 20 August 2018
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 30 (3) , 184
Surveillance biologique de l’exposition professionnelle (SBEP) aux médicaments anticancéreux au sein d’un hôpital Mauritanien
- 20 August 2018
- Published by Elsevier in Toxicologie Analytique et Clinique
- Vol. 30 (3) , 184
Surveillance biologique de l’exposition professionnelle (SBEP) aux médicaments anticancéreux au sein d’un hôpital Mauritanien
- 11 July 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (17) , 4110-4117
Biomonitoring of occupational exposure to 5-FU by assaying α-fluoro-β-alanine in urine with a highly sensitive UHPLC-MS/MS method
5-Fluorouracil (5-FU) is one of the most widely used antineoplastic drugs handled by healthcare professionals (HCP). To monitor occupational exposure to 5-FU, a highly sensitive ESI-UHPLC-MS/MS method was developed for the assay of its main human metabolite, α-fluoro-β-alanine (FBAL), in urine. After a derivatization step, solid phase extraction was used for the urine. Good linearity (r > 0.996), precision (CV < 14.76%), and accuracy (bias < 12.16%) were achieved. The lower limit of quantification (LOQ), 20 pg ml−1, is the lowest one published to date. Seven urine samples from 73 HCP exposed to 5FU were positive for FBAL, indicating 5FU contamination (9.6%). FBAL urine concentrations ranged from 25 to 301 pg ml−1. Such an efficient analytical tool combining high specificity with high sensitivity is essential for the reliable detection and routine biological monitoring of healthcare professionals occupationally exposed to this widely used antineoplastic drug. This method allows biomonitoring of occupational exposure to 5-fluorouracil in a routine manner, with the aim of assessing the effectiveness of collective and individual protective measures.
- 11 July 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (17) , 4110-4117
Biomonitoring of occupational exposure to 5-FU by assaying α-fluoro-β-alanine in urine with a highly sensitive UHPLC-MS/MS method
5-Fluorouracil (5-FU) is one of the most widely used antineoplastic drugs handled by healthcare professionals (HCP). To monitor occupational exposure to 5-FU, a highly sensitive ESI-UHPLC-MS/MS method was developed for the assay of its main human metabolite, α-fluoro-β-alanine (FBAL), in urine. After a derivatization step, solid phase extraction was used for the urine. Good linearity (r > 0.996), precision (CV < 14.76%), and accuracy (bias < 12.16%) were achieved. The lower limit of quantification (LOQ), 20 pg ml−1, is the lowest one published to date. Seven urine samples from 73 HCP exposed to 5FU were positive for FBAL, indicating 5FU contamination (9.6%). FBAL urine concentrations ranged from 25 to 301 pg ml−1. Such an efficient analytical tool combining high specificity with high sensitivity is essential for the reliable detection and routine biological monitoring of healthcare professionals occupationally exposed to this widely used antineoplastic drug. This method allows biomonitoring of occupational exposure to 5-fluorouracil in a routine manner, with the aim of assessing the effectiveness of collective and individual protective measures.